What sets Portland, Oregon-based CytoDyn (CYDY) apart from the pack is its pipeline of three ground-breaking therapies, PRO 140 and Cytolin entry-inhibitor antibodies for R5 HIV-1 (the most common, most virulentstrain of HIV worldwide).
But will the Fed's tactics of fighting deflation (which is intrinsically a good thing for creditors) through monetary inflation ignite a virulent new strain of inflation (which kills bond returns and drives down their prices)?